Lyell Immunopharma, Inc. announced positive clinical data for rondecabtagene autoleucel (ronde-cel) in patients with large B-cell lymphoma. The data showed a 93% overall response rate and 76% complete response rate in the 3L+ setting, along with a manageable safety profile. A Phase 3 trial is underway to compare ronde-cel with other CAR T-cell therapies. Additionally, translational data highlighted the potential of ronde-cel to improve outcomes for patients. The company will host an investor webcast to discuss these findings on December 8th at 8:30 AM ET. Overall, ronde-cel shows promise as a next-generation CAR T-cell therapy for cancer patients.

Read more at GlobeNewswire: Lyell Immunopharma Presents New Clinical Data from Ongoing